An open-label study of botulinum toxin A for treatment of tardive dystonia

D. Tarsy, D. Kaufman, K. D. Sethi, M. H. Rivner, E. Molho, S. Factor

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Tardive dystonia is a form of tardive dyskinesia for which there is little satisfactory treatment. We reviewed our experience at four movement disorder centers in the treatment of tardive dystonia with botulinum toxin A (BTX-A). Thirty-four patients with relatively localized tardive dystonia unresponsive to oral medications were treated with injections of BTX-A into dystonic muscles. Cervical dystonia was the most frequent manifestation of tardive dystonia in this group of patients. There was marked or moderate improvement in 29 of 34 patients. Eighteen of 24 patients with cervical dysionia showed either marked or moderate improvement. In this retrospective review, BTX-A provided useful symptomatic treatment for localized dystonia in patients with tardive dystonia unresponsive to other treatment. A controlled, prospective trial of BTX-A in tardive dystonia is warranted.

Original languageEnglish (US)
Pages (from-to)90-93
Number of pages4
JournalClinical neuropharmacology
Issue number1
StatePublished - Jan 1 1997


  • Botulinum toxin
  • Neuroleptic drugs
  • Tardive dyskinesia
  • Tardive dystonia

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'An open-label study of botulinum toxin A for treatment of tardive dystonia'. Together they form a unique fingerprint.

Cite this